Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB [NASD]
Biogen Idec Inc.
IndexS&P 500 P/E33.59 EPS (ttm)12.38 Insider Own0.10% Shs Outstand234.61M Perf Week1.76%
Market Cap97.55B Forward P/E20.88 EPS next Y19.91 Insider Trans-7.78% Shs Float234.41M Perf Month17.70%
Income2.93B PEG1.88 EPS next Q3.91 Inst Own92.10% Short Float1.40% Perf Quarter36.36%
Sales9.70B P/S10.05 EPS this Y58.40% Inst Trans-0.80% Short Ratio1.91 Perf Half Y21.85%
Book/sh45.90 P/B9.06 EPS next Y17.39% ROA22.10% Target Price419.83 Perf Year22.05%
Cash/sh7.87 P/C52.86 EPS next 5Y17.83% ROE29.40% 52W Range272.02 - 416.82 Perf YTD22.49%
Dividend- P/FCF36.75 EPS past 5Y29.90% ROI26.20% 52W High-1.37% Beta1.03
Dividend %- Quick Ratio1.70 Sales past 5Y17.30% Gross Margin87.90% 52W Low51.14% ATR9.38
Employees7550 Current Ratio2.10 Sales Q/Q34.30% Oper. Margin40.40% RSI (14)66.51 Volatility2.03% 2.40%
OptionableYes Debt/Eq0.05 EPS Q/Q94.80% Profit Margin30.20% Rel Volume0.77 Prev Close415.79
ShortableYes LT Debt/Eq0.05 EarningsJan 29 AMC Payout0.00% Avg Volume1.72M Price411.13
Recom2.00 SMA202.57% SMA5011.05% SMA20023.11% Volume99,115 Change-1.12%
Feb-02-15Reiterated Argus Buy $385 → $440
Jan-30-15Reiterated RBC Capital Mkts Outperform $400 → $445
Jan-30-15Reiterated Deutsche Bank Buy $430 → $460
Oct-22-14Upgrade Robert W. Baird Neutral → Outperform $374 → $382
Aug-19-14Resumed Stifel Buy $376
Jul-29-14Reiterated Argus Buy $360 → $385
Jul-24-14Reiterated UBS Neutral $330 → $354
Jul-09-14Reiterated RBC Capital Mkts Outperform $325 → $375
Mar-19-14Reiterated Stifel Buy $360 → $376
Mar-07-14Reiterated Barclays Overweight $325 → $352
Mar-03-14Reiterated Stifel Buy $330 → $360
Jan-30-14Reiterated UBS Neutral $300 → $310
Jan-30-14Reiterated Brean Capital Buy $293 → $377
Jan-30-14Reiterated Argus Buy $310 → $360
Jan-28-14Reiterated Deutsche Bank Buy $340 → $415
Jan-27-14Reiterated Canaccord Genuity Buy $291 → $355
Jan-16-14Reiterated Stifel Buy $296 → $321
Jan-10-14Reiterated Barclays Overweight $285 → $325
Dec-20-13Reiterated RBC Capital Mkts Outperform $275 → $325
Dec-12-13Reiterated Argus Buy $280 → $310
Mar-03-15 02:11AM  German Merck sees slight gain in 2015 core profit Reuters
Mar-02-15 06:44PM  Big Cap 20 Reflecting Market Leadership at Investor's Business Daily
02:52PM  Gilead Sciences (GILD), AstraZeneca (AZN), Bellicum Pharmaceuticals (BLCM): Redmile Groups Top New Picks at Insider Monkey
02:10PM  Biogen/Sobi Report Postive Phase III Data on Alprolix - Analyst Blog Zacks
10:40AM  Isis Pharmaceuticals Up on Q4 Earnings and Revenues Beat - Analyst Blog Zacks
Feb-27-15 07:09AM  Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase 3 Alprolix┬« paediatric study Thomson Reuters ONE
07:00AM  Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 ALPROLIX┬« Pediatric Study Business Wire
Feb-26-15 09:56AM  Medivation Tops Q4 Views On Strong Xtandi Results at Investor's Business Daily
09:30AM  Neurotrope Moving Focus Upstream in Developing New Alzheimers Disease Drug and Drugs for Orphan Diseases Company Spotlight
09:25AM  Short Sellers Increase Bets Against Biotech as Shares Continue to Rise at 24/7 Wall St.
Feb-25-15 09:56AM  13F Filings Takeaway: Own A Dirty Dozen at Forbes
Feb-24-15 07:47PM  Nasdaq nears its Internet bubble-era record at Fortune
01:15PM  These five stocks are in the Nasdaq driver's seat at CNBC
10:04AM  United Therapeutics Blood Pressure Drug Lifts Q4 at Investor's Business Daily
07:03AM  What's driving the Nasdaq? These 5 stocks CNBC
Feb-23-15 07:58PM  Gilead Sciences, Inc., Amgen, Inc., Biogen Idec Inc Among Billionaires 5 Hottest Biotech Picks at Insider Monkey
06:19PM  Cramer: We're in a bubble. So, what? Apple's cheap at CNBC
04:49PM  Monday's Market Recap Yahoo Finance Contributors
04:01PM  Biogen Idec to Present at the Cowen and Company 35th Annual Healthcare Conference Business Wire
02:59PM  Drugmaker Mylan Takes Part In Pharma Feeding Frenzy at Investor's Business Daily
02:31PM  Nasdaq's biggest drivers CNBC
12:18PM  Nasdaq: Why this time is different CNBC
Feb-20-15 04:42PM  Friday's Market Recap Yahoo Finance Contributors
Feb-19-15 02:05PM  Biogen Idec, Columbia University and HudsonAlpha Institute Identify New ALS Gene and Signaling Pathways Business Wire
Feb-18-15 05:10PM  Business Journal names Healthiest Employers 2015 at American City Business Journals
Feb-17-15 04:01PM  Biogen Idec to Present at the 2015 RBC Capital Markets Global Healthcare Conference Business Wire
Feb-16-15 07:15PM  Billionaire Stanley Druckenmillers Top 5 Picks Include Biogen Idec Inc (BIIB), Target Corporation (TGT), Home Depot Inc (HD) at Insider Monkey
Feb-13-15 09:26AM  Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog Zacks
09:22AM  Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog Zacks
Feb-12-15 04:23PM  Sucampo, Par Pharmaceuticals Enter License Agreement - Analyst Blog Zacks
12:40PM  Oncolytics' Reolysin Gets Orphan Status for Ovarian Cancer - Analyst Blog Zacks
Feb-11-15 04:22PM  Stocks End Mixed: Molina Healthcare Rises Again at Investor's Business Daily
02:42PM  Isis Pharma to Get $5M from Biogen - Analyst Blog Zacks
01:04PM  BIOGEN IDEC INC. Financials EDGAR Online Financials
10:36AM  Stocks Open Mixed, Techs Climb; Rite Aid, Akamai, AmTrust Jump at Investor's Business Daily
09:54AM  Charles River (CRL) Beats on Q4 Earnings and Revenues - Analyst Blog Zacks
Feb-10-15 04:38PM  Regeneron Earnings Growth Falls Short, But Eylea Sales, '15 Outlook Are Solid Investor's Business Daily
04:30PM  Orexigen Gives Positive Updates on its Weight Loss Drug - Analyst Blog Zacks
04:20PM  Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog Zacks
03:59PM  Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog Zacks
11:01AM  Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea at Investor's Business Daily
Feb-09-15 01:10PM  Will Sangamo (SGMO) Disappoint This Earnings Season? - Analyst Blog Zacks
08:32AM  Developers #HackMS at the First Ever Hackathon for Multiple Sclerosis PR Newswire
Feb-06-15 07:07PM  10-K for Biogen Idec, Inc. Company Spotlight
06:29PM  No Deceleration Here: 14 Stocks With Accelerating Profits at Investor's Business Daily
10:10AM  Stock Market News for February 06, 2015 - Market News Zacks
09:04AM  Sanofi Misses on Q4 Earnings, Maintains Diabetes Guidance - Analyst Blog Zacks
09:01AM  Teva Beats on Q4 Earnings By a Penny, Maintains Outlook - Analyst Blog Zacks
02:01AM  Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs - ETF News And Commentary Zacks
Feb-05-15 06:20PM  bluebird bio's Thalassemia Drug Gets Breakthrough Status - Analyst Blog Zacks
02:38PM  Biogen Idec: Under-Owned, Unappreciated at Barrons.com
10:15AM  Perrigo Beats on Earnings, FY15 Guidance In Line - Analyst Blog Zacks
09:52AM  Allergan Beats Earnings Yet Again on Strong Revenues - Analyst Blog Zacks
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Biogen, Celgene, AbbVie and Gilead - Press Releases Zacks
Feb-04-15 04:40PM  BIOGEN IDEC INC. Files SEC form 10-K, Annual Report EDGAR Online
11:47AM  Biotech Stock Roundup: Biogen Impresses with 4Q Results, Gilead & AbbVie HCV Drugs in Focus - Analyst Blog Zacks
11:21AM  Merck (MRK) Beats on Q4 Earnings but Guidance Falls Short - Analyst Blog Zacks
08:29AM  Will Biogen (BIIB) Continue to Surge Higher? - Tale of the Tape Zacks
Feb-03-15 04:49PM  Paying Dividends: Gilead Initiates First Quarterly Payout at Barrons.com
Feb-02-15 04:32PM  Monday's Market Recap Yahoo Finance Contributors
08:51AM  Biogen Idec (BIIB) Shows Strength: Stock Moves Up 10.2% - Tale of the Tape Zacks
08:00AM  Regulus Earns Milestone Payment from Biogen Idec Related to the Identification of Potential microRNA Biomarkers in Multiple Sclerosis PR Newswire
Jan-31-15 08:02AM  Super Bowl Stocks: Seattle's Best Vs. Boston Strong at Investor's Business Daily
Jan-30-15 05:51PM  Friday's Market Recap Yahoo Finance Contributors +10.17%
03:14PM  Is the 'January Effect' Signaling a Down Year for the Stock Market? at TheStreet
01:47PM  Indexes Mired In Red; Amazon, Biogen, Visa Buck Trend at Investor's Business Daily
01:15PM  As Biogen shares hit all-time high, profits and headcount grow, too at American City Business Journals
12:15PM  Upside play in biotech space CNBC
12:01PM  Stocks Extend Losses; Biogen Idec Gains at Investor's Business Daily
11:45AM  Biogen, Intercept post double-digit gains at MarketWatch
11:40AM  Biogen Tops Q4 Earnings, Provides Strong Outlook for 2015 - Analyst Blog Zacks
11:13AM  Biogen Idec (BIIB) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
10:38AM  Cramer: Shares of Biogen Head Higher; Questions Surround Deckers at TheStreet
10:37AM  Stocks Open Down In Weak Trade; Biogen, Visa Soar On Q4 Results at Investor's Business Daily
10:35AM  Did Biogen Run Too Much After Earnings? 24/7 Wall St.
09:23AM  Cramer's Mad Dash: BIIB & DECK CNBC
09:06AM  Morning Movers: Stocks Slip On GDP News; MasterCard, Visa Biogen Jump at Barrons.com
Jan-29-15 06:49PM  Biogen, Alexion Earnings Top Views, Shares Jump Investor's Business Daily
05:47PM  Biogen Idec to add 100 jobs in RTP at American City Business Journals
05:32PM  Biogen's Profit Nearly Doubles at The Wall Street Journal
05:27PM  Biogen tops 4Q profit forecasts AP
04:33PM  Biogen forecasts 2015 earnings well ahead of Street view Reuters
04:30PM  Biogen shares jump after company reports earnings at MarketWatch
04:30PM  Biogen Idec Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:05PM  BIOGEN IDEC INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:01PM  Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion Business Wire
01:28PM  Alexion Beats Q4 Estimates, Appoints New CEO at Investor's Business Daily
10:23AM  Credit Suisse Previews Biogen, Says 'Consensus Tecfidera Downgrades = Pipeline Buying Opportunity' Benzinga
10:10AM  Vertex Posts Wider 4Q Loss, Affirms Kalydeco Outlook - Analyst Blog Zacks
07:07AM  Q4 2014 Biogen Idec Inc Earnings Release - After Market Close CCBN
04:40AM  Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Global Collaboration to Develop Gene Therapies for Hemophilia Business Wire
Jan-28-15 03:00PM  What to Watch in the Day Ahead - Thursday, Jan. 29 Reuters
08:00AM  NFL Hall of Famer Earl Campbell And Son Tyler Campbell Pair Up With Biogen Idec To Celebrate The Inspiring Stories Of People With Relapsing Multiple Sclerosis PR Newswire
06:05AM  Up to Speed: Peltz receives ammo in fight against DuPont (Video) at American City Business Journals
Jan-27-15 12:00PM  Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst Blog Zacks
09:00AM  Google, Biogen Seek Reasons for Advance of Multiple Sclerosis at Bloomberg
Jan-26-15 06:42PM  Big Cap Stocks Mylan, American Tower Near Buy Points at Investor's Business Daily
05:51PM  Biogen Idec Earnings: What to Watch at The Wall Street Journal
05:25PM  CORRECTING AND REPLACING Biogen Idec to Report Fourth Quarter and Year End 2014 Financial Results on January 29, 2015 Business Wire
08:02AM  Apple, Facebook Lead This Week's IBD 50 Earnings at Investor's Business Daily
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company's products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer's disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCANGOS GEORGE AChief Executive OfficerFeb 19Sale401.04537215,35846,538Feb 20 04:28 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale389.11825321,01647,075Feb 18 04:45 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 17Sale389.112,128828,0264,321Feb 18 04:41 PM
DiPietro KennethEVP Human ResourcesFeb 17Sale389.111,188462,263803Feb 18 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 17Sale389.11418162,64815,004Feb 18 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.0015,599045,547Feb 17 09:32 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.0047101,450Feb 17 09:16 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.003,63407,152Feb 17 08:54 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,20101,318Feb 17 08:50 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.001,605015,805Feb 17 08:47 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.004,299022,960Feb 17 08:44 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,738033,214Feb 17 08:40 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.005,200016,481Feb 17 08:37 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.003,769028,634Feb 17 08:34 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,76402,706Feb 17 08:30 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.003,60108,771Feb 17 08:26 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833043,148Feb 11 04:25 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 10Sale398.111,143455,03914,574Feb 11 04:26 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270029,255Feb 11 04:25 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691032,744Feb 10 05:07 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691022,194Feb 10 05:06 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,82407,088Feb 10 05:08 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,398Feb 10 05:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909027,716Feb 10 05:12 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Sale398.05856340,73114,574Feb 10 05:11 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468014,542Feb 10 05:14 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277015,851Feb 10 05:11 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70505,802Feb 10 05:10 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,63606,147Feb 10 05:08 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498024,625Feb 10 05:12 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191018,646Feb 10 05:06 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023029,590Feb 10 05:07 PM
DiPietro KennethEVP Human ResourcesFeb 02Sale389.031,656644,2340Feb 03 06:35 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 02 07:46 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,157013,133Feb 02 07:43 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,15705,157Feb 02 07:40 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerDec 15Sale346.501,981686,417352Dec 16 04:36 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale345.88440152,18714,574Dec 05 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentDec 02Sale335.651,749587,0520Dec 03 04:32 PM
Holtzman Steven HEVP Corporate DevelopmentNov 11Sale330.001,750577,5001,749Nov 12 04:24 PM
SCANGOS GEORGE AChief Executive OfficerNov 03Sale320.781,128361,84017,985Nov 04 04:18 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale330.971,127373,00319,113Oct 02 04:44 PM
Holtzman Steven HEVP Corporate DevelopmentOct 01Sale330.971,750579,1983,499Oct 02 04:42 PM
SCANGOS GEORGE AChief Executive OfficerSep 02Sale345.471,128389,69020,240Sep 04 04:15 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale332.931,128375,54521,368Aug 04 04:43 PM
SCANGOS GEORGE AChief Executive OfficerJul 16Sale312.3712,3163,847,14922,496Jul 18 05:59 PM
SCANGOS GEORGE AChief Executive OfficerJul 15Option Exercise0.0021,339044,874Jul 17 04:45 PM
Posner Brian SDirectorJun 20Sale315.00605190,5756,000Jun 23 04:37 PM
Posner Brian SDirectorJun 13Sale310.50700217,3506,605Jun 16 04:37 PM
SCANGOS GEORGE AChief Executive OfficerJun 02Sale318.93484154,36223,535Jun 03 04:29 PM
Holtzman Steven HEVP Corporate DevelopmentMay 19Sale289.151,221353,0525,749May 20 04:16 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise286.7534799,5021,029May 02 04:20 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale285.562,123606,24124,019May 02 04:22 PM
Holtzman Steven HEVP Corporate DevelopmentApr 17Sale291.001,221355,3116,970Apr 21 05:07 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,677Apr 03 04:27 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale308.422,123654,77626,142Apr 02 04:16 PM
Posner Brian SDirectorMar 31Sale296.763,000890,2756,435Apr 01 04:15 PM
DORSA CAROLINEDirectorMar 20Option Exercise53.6410,000536,40024,468Mar 21 04:17 PM
DORSA CAROLINEDirectorMar 20Sale348.8810,0003,488,81314,468Mar 21 04:17 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentMar 19Sale352.293,5051,234,7767,976Mar 21 04:15 PM
Holtzman Steven HEVP Corporate DevelopmentMar 17Sale334.831,221408,8278,191Mar 18 05:08 PM
Kingsley Stuart AEVP, Global Comm. OperationsMar 11Sale336.838,4282,838,7663,511Mar 12 07:15 PM
SCANGOS GEORGE AChief Executive OfficerMar 10Sale333.7726,1248,719,37828,265Mar 12 07:20 PM
LEAMING NANCYDirectorMar 10Sale327.652,000655,3007,660Mar 12 07:16 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 04Sale342.583,1711,086,32115,407Mar 05 03:12 PM